

CITATION REPORT

List of articles citing

Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2-Advanced Breast Cancer From a US Payer Perspective

DOI: 10.1016/j.clbc.2015.04.001

Clinical Breast Cancer, 2015, 15, e263-76.

Source: <https://exaly.com/paper-pdf/62098597/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. <i>Journal of Medical Economics</i> , 2016 , 19, 414-23	2.4	2
19	Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. <i>Advances in Therapy</i> , 2016 , 33, 983-97	4.1	7
18	Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 51-57	4.4	23
17	Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan. <i>Pharmacoeconomics</i> , 2018 , 36, 1113-1124	4.4	2
16	Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019 , 25, 511-522	1.9	36
15	Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2018 , 34, 2143-2150	2.5	6
14	Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018 , 69, 204-214	14.4	34
13	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. <i>Breast Cancer Management</i> , 2019 , 8, BMT22	0.7	4
12	Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 633-643	2.2	0
11	Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 775-779	4.4	21
10	An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 343-355	4.4	6
9	Evidence-based sizing of non-inferiority trials using decision models. <i>BMC Medical Research Methodology</i> , 2019 , 19, 3	4.7	3
8	Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. <i>Journal of Clinical Oncology</i> , 2020 , 38, 332-350	2.2	9
7	First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 340-348	2.7	10
6	First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis. <i>Clinical Breast Cancer</i> , 2021 , 21, e479-e488	3	2
5	Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , 2019 , 6, 20-31	1.6	4
4	Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Annals of Translational Medicine</i> , 2021 , 9, 1493	3.2	0

3	Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis. 2023 , 168, 17-22	o
2	Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. 20-31	o
1	Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression. 2023 ,	o